Literature DB >> 2890459

Absorption studies of the H2-blocker nizatidine.

M P Knadler1, R F Bergstrom, J T Callaghan, B D Obermeyer, A Rubin.   

Abstract

The absolute and relative bioavailability of nizatidine, an H2-blocker, was studied in healthy male volunteers. The absolute oral bioavailability, relative to that after intravenous administration, was 98% +/- 14%. The bioavailability of single and multiple oral doses of 150 mg nizatidine was unaffected by concurrent food ingestion; nizatidine may be administered either with or without food. The relative bioavailability of nizatidine was compared when given simultaneously with placebo or Gelusil, 30 minutes after propantheline, or 60 minutes before activated charcoal. Gelusil reduced the amount of nizatidine absorbed by about 10%, charcoal reduced it by about 30%, and propantheline did not affect it.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890459     DOI: 10.1038/clpt.1987.190

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A H Price; R N Brogden
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

4.  Modulation of the tight junctions of the Caco-2 cell monolayers by H2-antagonists.

Authors:  L S Gan; S Yanni; D R Thakker
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

Review 5.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Gastric fluid volume and pH after nizatidine in adults undergoing elective surgery: influence of timing and dose.

Authors:  K Mikawa; K Nishina; N Maekawa; M Asano; H Obara
Journal:  Can J Anaesth       Date:  1995-08       Impact factor: 5.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.